statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic five-year collaboration agreement...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common...

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. It is an honor to add Jeff...

Futures Rise To Start June As Nvidia Jumps, Gamestop Soars

Futures Rise To Start June As Nvidia Jumps, Gamestop Soars

 After closing the month of May on the front-foot when a last minute rebalancing spike in the S&P reversed two days of losses...

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222...

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, Ivonescimab Plus Chemotherapy...

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China...

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly...

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today announced the grant of inducement awards of options to purchase a collective total of up to 200,000 shares of common...

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Volume	3.2M
52-Wk High	$11.25
52-Wk Low	$1.52

SMMT Summit Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals